Adagene

Adagene ROA

The Return on Assets (ROA) of Adagene (ADAG) as of Nov 3, 2026 is -22.50 %. In the previous year, Return on Assets (ROA) was -37.44 % — a change of -39.91% (higher).

ROA

-22.50 %

YoY

-39.91%

Last updated:

In 2025, Adagene's return on assets (ROA) was -22.50 %, a -39.91% increase from the -37.44 % ROA in the previous year.

The Adagene ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-27.05 USD
Jan 1, 2019
-16.33 USD
Jan 1, 2020
-19.51 USD
Jan 1, 2021
-38.61 USD
Jan 1, 2022
-52.48 USD
Jan 1, 2023
-16.37 USD
Jan 1, 2024
-37.44 USD
Jan 1, 2025
-22.50 USD
The Adagene ROA history
YEARROAYoY
-22.50 %-39.91%
-37.44 %+128.71%
-16.37 %-68.80%
-52.48 %+35.90%
-38.61 %+97.97%
-19.51 %+19.43%
-16.33 %-39.62%
-27.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adagene Stock analysis

What does Adagene do? Adagene Inc. develops monoclonal antibody drugs for cancer treatment in China, focusing on clinical-stage products. Its lead candidate ADG126, a masked anti-CTLA-4 mAb, is in phase 1b/2 trials for cancer. The company also advances ADG116, a fully human anti-CTLA-4 antibody using NEObody technology, in phase 1b/2 for solid tumors. ADG206 targets advanced metastatic solid tumors in phase 1, while ADG104, an anti-PD-L1 antibody, is in phase 2 development. Additional candidates include ADG125 for phase 2 studies, ADG138 for low-expressing tumors, and ADG152 for off-tumor toxicities, all in preclinical stages. The company's pipeline targets various cancer types through innovative antibody technologies. Adagene generates revenue through the development and commercialization of its antibody drug candidates. It focuses on clinical trials for products like ADG126, ADG116, and ADG104, aiming to secure partnerships with pharmaceutical companies for later-stage development and marketing. The company's products target advanced cancer treatments, appealing to oncology-focused pharmaceutical firms seeking novel therapies. ADG153, a masked anti-CD47 antibody, and CD28 T-cell engagers represent further pipeline opportunities for collaboration in oncology drug development. Adagene's business model centers on advancing its pipeline through clinical trials to attract potential partners. The company's focus on anti-CTLA-4, anti-PD-L1, and novel antibody technologies positions it for strategic collaborations. Its products target unmet needs in cancer treatment, particularly for resistant or metastatic tumors. The company's preclinical and clinical-stage candidates, including ADG138 and ADG152, are designed to address specific oncology challenges, making them attractive for pharmaceutical partnerships. Adagene is one of the most popular companies on Eulerpool.

ROA Details

Understanding Adagene's Return on Assets (ROA)

Adagene's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Adagene's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Adagene's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Adagene’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Adagene stock

Return on Assets (ROA) of Adagene is -22.50 % in 2025.

Return on Assets (ROA) of Adagene changed from -37.44 % to -22.50 %, representing a -39.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Adagene since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Adagene with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Adagene

All Key Metrics — Adagene